Dr Menelas N Pangalos FMedSci – Speaker Profile (2016)
Mene Pangalos, Ph.D. is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit. A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s small molecule discovery research and early development activities.
Since joining AstraZeneca in 2010, Mene has been instrumental in transforming the company’s commitment to science. He has led the transformation of R&D productivity through the development and implementation of the “5R” framework (recently published in Nature Reviews Drug Discovery); driven greater collaboration with academic, NGO and peer organisations; pioneered programmes to promote more open innovation and fostered a science driven culture that rewards truth-seeking behaviours.
As one of AstraZeneca’s leading scientists, Mene has published more than 140 peer-reviewed articles in scientific journals and has served as an editor of books and journals in neuroscience.
Mene is also a leading figure in UK science, and is a Fellow of the Academy of Medical Sciences and of the Royal Society of Biology. He is a Visiting Professor of Neuroscience at King’s College London and is a Fellow of Clare Hall at the University of Cambridge. Mene serves on the Medical Research Council (MRC), the council for the National Centre for Universities and Business, the Prime Minister’s Research Champion Group for Dementia, and is part of the Ministerial Industry Strategy Group, and is a Non-Executive Director of the UK Precision Medicine Catapult.
Mene is also overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.